“Chong Kun Dang Acquires Januvia Copyright from MSD Korea Sparking Diabetes Division Disbandment and ERP Implementation”

Januvia (ingredient: sitagliptin), which had been dominant in the type 2 diabetes treatment market, left MSD Korea and moved to the nest of domestic pharmaceutical company Chong Kun Dang. With Januvia’s attribution to Chong Kun Dang, MSD Korea’s diabetes division was found to be disbanding.

Regarding this, it is known that MSD Korea plans to implement ERP for the personnel in the diabetes division from next month. ERP conditions are expected to present the highest level in the industry.

According to related industries on the 10th, Chong Kun Dang completed the introduction of licenses for the domestic sales and manufacturing rights of Januvia, a diabetes treatment, on the 9th.

With this license agreement, Chong Kun Dang has the domestic copyright, distribution rights, licensing rights, trademark rights, and manufacturing license rights for the Januvia series, such as Januvia, Janumet, and Janumet XR, which were previously held by MSD Korea.

The contract amount between Chong Kun Dang and MSD Korea for the relocation of Januvia is worth 45.5 billion won, and Chong Kun Dang plans to pay MSD 22.5 billion won for milestones according to sales along with a down payment of 23 billion won.

Previously, Chong Kun Dang had been supplying Januvia in Korea through a co-promotional contract with MSD Korea since 2016. With this copyright agreement, Chong Kun Dang will be solely in charge of sales and marketing of the Januvia portfolio from July 15 this year.

Sales of the Januvia series last year amounted to 138.6 billion won, and the patent is about to expire in September.

With the transfer of Chong Kun Dang’s copyright for the Januvia series, MSD Korea is expected to strategically focus on innovative medicines.

According to related industries, MSD Korea plans to disband the diabetes business department with the transfer of Januvia’s copyright and reorganize it into anticancer agents, vaccines, and hosipital specialty businesses to enhance competitiveness.

In addition, the ERP of the personnel who carried out the diabetes part project is also promoted.

An industry insider said, “As the diabetes division, which was the main business unit of MSD Korea, was disbanded due to the transfer of the copyright for Januvia, we plan to implement ERP for the personnel in that department.” scheduled,” he said.